Alumis Psoriasis Treatment Shows Leading Skin Clearance Rates
Alumis releases long-term data for psoriasis drug envudeucitinib, boasting top skin clearance rates ahead of a Q4 FDA filing with FDA.
Alumis's psoriasis medicine is working really well and clearing up skin better than competitors—now they're ready to ask the government for permission to sell it. When a medicine gets strong results like this, it hints the company could have a real product people need, though we won't know for sure until regulators decide.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.